Glaxo: Power brand strategy pays off - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Glaxo: Power brand strategy pays off

Feb 19, 2004

GlaxoSmithKline Pharmaceuticals (Glaxo) recently announced its quarter and year ending FY04 results. For 4QFY04, while the topline grew by 8% YoY, the company did well to turn out profits after the losses that it had incurred in the same period of FY03. The profit growth for FY04 was better still at 76% YoY. This came on back of the company improving upon its revenues by 4% for this period. This growth in topline compbined with reduction on the expenditure front helped Glaxo to improve its operating margins for FY04 by 570 basis points. The improvement on the margins front was much better at 1,040 basis points for the fourth quarter.

Financial performance: A snapshot
(Rs m)4QFY034QFY04ChangeFY03FY04Change
Sales 2,290 2,466 7.7% 11,482 11,917 3.8%
Other Income 145 161 10.8% 427 544 27.3%
Expenditure 2,104 2,010 -4.5% 9,751 9,436 -3.2%
Operating Profit (EBDIT) 186 456 145.7% 1,731 2,481 43.3%
Operating Profit Margin (%)8.1%18.5%-15.1%20.8%-
Interest 00-00-
Depreciation 46 49 7.0% 195 179 -7.9%
Profit before Tax28556899.3%1,9632,84644.9%
Extraordinary items (251) (219)- (304) (96)-
Tax 68 202 196.5% 679 1,027 51.3%
Profit after Tax/(Loss) (35) 146 981 1,722 75.6%
Net profit margin (%)-1.5%5.9%8.5%14.5%
No. of Shares 74.7 74.7 74.7 74.7
Diluted Earnings per share* (Rs)-1.97.813.123.1
P/E Ratio (x) 27.2
(* annualised)

The growth in topline for FY04 was a result of the company's pharmaceuticals business growing by 6% YoY. The growth in this business, which constitutes to around 82% of Glaxo's total revenues, negated the 5% decline in revenues from the company's other businesses segment (18% of revenues). This segment caters to areas like veterinary formulations, feed supplements, diagnostics and lab equipments. Growth of the pharmaceuticals segment was driven basically by the 30 priority products (including brands like Augmentin) of the company that registered double-digit growth. Another growth driver from the pharma business was the company's vaccines range where the company rolled out a concept of 'Famili Vaccines' an immunisation awareness initiative.

Segmental performance
(Rs m)FY03FY04Change
Revenue 9,401 9,970 6.1%
PBIT 1,620 2,373 46.5%
PBIT margins17.2%23.8%
Other businesses
Revenue 2,388 2,262 -5.3%
PBIT 394 445 12.9%
PBIT margins16.5%19.7%
Revenue 11,789 12,232 3.8%
PBIT 2,013 2,818 39.9%
PBIT margins17.1%23.0%
* Excluding inter-segment adjustments

On the profitability front, Glaxo has been able to improve its operating margins by substantial measures. And this is mainly a result of decline on the material consumed and other expenses fronts. While the former declined (as a percentage of sales) by around 2%, the drop in the latter was larger at around 8%. Based on segments, while PBIT margins for the pharmaceuticals segment improved by 660 basis points, the improvement in margins for Glaxo's other businesses was a substantial 320 basis points. The company's stated strategy of focusing on 30 power brands (reminds one of HLL) seems to be bearing fruit and driving profitability.

Cost break-up
(Rs m)FY03FY04Change
Materials consumed 5,031 4,943 -1.7%
% Of sales43.8%41.5%
Staff costs 1,313 1,301 -0.9%
% Of sales11.4%10.9%
Excise duty 1,010 985 -2.4%
% Of sales8.8%8.3%
Other expenses 2,497 2,307 -7.6%
% Of sales21.7%19.4%
Total expenses* 9,851 9,536 -3.2%
% Of sales85.8%80.0%
* Excluding recovery of expenses

The improvement in Glaxo's FY04 margins would have been better but for the fact that the National Pharmaceuticals Pricing Authority (NPPA) revised downwards the prices of Ranitidine formulations in the third quarter (ending September 2003). This affected the margins of Zinetac, one of the important products of Glaxo.

At the current price of Rs 627, the stock is trading at a P/E multiple of 27.2x its FY04 earnings. The company has declared a dividend of Rs 10 per equity share for FY04 (Rs 7 in FY03). The company is in advanced stages of negotiations for its Worli property in Mumbai, which is expected to give its extraordinary income a fillip in FY05. Glaxo is gearing itself towards 2005, when the patent regime comes into force. The company is also likely to finalise the much awaited merger with Burroughs Wellcome soon. Though the valuations seem at the upper end of the spectrum, future benefits during the patent regime post 2005 is keeping the investor interest alive.

Equitymaster requests your view! Post a comment on "Glaxo: Power brand strategy pays off ". Click here!


More Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.


India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms


Jun 17, 2021 10:18 AM


  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks